#United States #Washington #Novo Nordisk #Wegovy #CagriSema

Novo's Innovative Presentation at ObesityWeek 2026

Novo Nordisk is set to shine a spotlight on its latest advancements in obesity treatment at the upcoming ObesityWeek 2026, happening from November 14 to 17 in Washington, D.C. This event is a pivotal platform where researchers, healthcare professionals, and advocates gather to share insights and advancements in the field of obesity.

The company's unveiling will include 26 comprehensive abstracts focusing on two main investigational drugs: CagriSema and Wegovy®. CagriSema is an innovative treatment still undergoing investigation, while Wegovy® is already familiar in the medical community for its promising results in combating obesity.

Key Highlights and Findings

1. CagriSema’s Performance
- The REDEFINE clinical program will showcase principal results of trials that test lower doses of CagriSema in adults dealing with overweight or obesity. Significant focus will be on the changes in quality of life correlating with weight management, aiming to understand the psychological and physical impacts of obesity.

2. Wegovy® Real-World Findings
- The event will also present real-world data on Wegovy®, particularly its administration through both pills and injections. New analyses will outline how older adults respond to these treatments, especially in terms of food-related behaviors and preferences between different obesity medications.
- Notably, studies will explore the challenges associated with